Alnara Therapeutics, Inc.: Series B $35M

Posted in I - Series B, Q - 1Q10, R - NORTH EAST, X - CF, X - Pancreas, XX - MA

Alnara Therapeutics (Cambridge, MA) a clinical-stage biopharmaceutical company focused on liprotamase, a pancreatic enzyme replacement therapy, for the treatment of pancreatic insufficiency associated with cystic fibrosis, chronic pancreatitis, pancreatic cancer, pancreatectomy and other pancreatic conditions, closed a $35M Series B financing. Participants include MPM Capital, Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners.

Feb

2010

PTC Therapeutics, Inc.: Series E $50M

Posted in I - Series E, Q - 4Q09, R - NORTH EAST, X - CF, X - Hemophilia, X - Muscular Dystrophy, XX - NJ

PTC Therapeutics (South Plainfield, NJ) a clinical-stage small molecule company focused on CF, hemophilia and muscular dystrophy, closed a $50M Series E financing. Participants include The Column Group, Delphi Ventures, CSFB Private Equity, HBM BioVentures and Novo Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Apr

2009

Aerovance, Inc.: Series C $38M

Posted in I - Series C, Q - 2Q09, R - WEST, X - Asthma, X - CF, X - COPD, X - Eczema, XX - CA

Aerovance (Berkeley, CA) a clinical-stage company focused on respiratory and allergic diseases, closed a $38M Series C financing. Participants include ProQuest Investments, BB Biotech Ventures, Apax Partners, Clarus Ventures, Alta Partners, Lehman Brothers, NGN Capital and Burrill & Co.

Feb

2009

Mpex Pharmaceuticals, Inc.: Series D $27.5M

Posted in I - Series D, Q - 1Q09, R - WEST, X - Antibacterial, X - CF, X - COPD, XX - CA

Mpex Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on antibiotic therapy in patients with cystic fibrosis and COPD, closed a $27.5M Series D financing. Participants include Investor Growth Capital, SV Life Sciences, HBM BioVentures, Aberdare Ventures and Adams Street Partners.

to top of page...